Quick Answer
Entrada Therapeutics, Inc. reported Net Income Loss of -$143.75 million for the year ending 2025.
- Entrada Therapeutics, Inc. showed a decrease of -319.0% in Net Income Loss from 2024 to 2025.
- This data is from Entrada Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Entrada Therapeutics, Inc.'s Net Income Loss has declined by 442.0%.
- Historical annual values: Fiscal year 2025: -$143.75 million | Fiscal year 2024: $65.63 million | Fiscal year 2023: -$6.69 million | Fiscal year 2022: -$94.62 million | Fiscal year 2021: -$51.16 million | Fiscal year 2020: -$26.52 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: